Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Apr 13;6:19612. doi: 10.1038/srep19612

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2016, Macmillan Publishers Limited

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

. Changes in the proportion of patients receiving cinacalcet are shown for 3 categories of serum iPTH at baseline (n = 1,948 for <300 pg/ml, n = 824 for 300–<500 pg/ml, and n = 504 for ≥500 pg/ml). Visit 0 indicates the baseline (December 2007). The time between visits was 3 months. In January 2008 (within visit 1), cinacalcet was approved for use in clinical practice in Japan. Data were derived from the subcohort (n = 3,276). The numbers of patients analyzed gradually decreased to 2,469 at visit 12, due to death, loss to follow-up, and other reasons.